XenoPort falls on XP13512 miss

XenoPort Inc. (NASDAQ:XNPT) fell $2.62 (15%) to $14.76 on Monday after data from a U.S. Phase II trial to treat painful diabetic neuropathy in 421 subjects showed that XP13512 ( GSK1838262) did not meet the primary endpoint of a significant change from baseline on the Pain Intensity Numerical Rating Scale (PI-NRS) compared with placebo. XenoPort and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said the 14-week, double-blind trial's failure may have been due to a high placebo response rate, noting the Lyrica pregabalin active control arm also did not did not demonstrate a significant change in the PI-NRS compared with placebo. XP13512 is a transported prodrug of gabapentin. Pfizer Inc. (NYSE:PFE) markets Lyrica. ...